A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group

D. H. Johnson, L. H. Einhorn, R. Birch, R. Vollmer, C. Perez, S. Krauss, G. Omura, F. A. Greco

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

To assess the effect of dose escalation in the treatment of small-cell lung cancer (SCLC), 298 patients with extensive-stage disease were treated with either conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2), (CDCAV); or high-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV). No dose attenuation was allowed during the initial three cycles of therapy in either treatment arm. All patients received CDCAV in cycles 4 through 6, during which time dosages were adjusted according to granulocyte and platelet nadirs. No additional chemotherapy was administered until disease progression or relapse was documented. Complete responses were more frequent with HDCAV (22% v 12%; P=.045). However, overall response rate (63% v 53%) and median survival (29.3 v 34.7 weeks) were not significantly different (P>.05). HDCAV was substantially more toxic than CDCAV, causing more episodes of life-threatening leukopenia (ie, granulocytes < 500/μL; 79% v 40%; P<.05) and infections (15% v 4%; P<.05). Dose intensification of cyclophosphamide and doxorubicin during induction chemotherapy did not produce any survival benefit compared with conventional dosages of these agents in SCLC patients with extensive-stage disease.

Original languageEnglish (US)
Pages (from-to)1731-1738
Number of pages8
JournalJournal of Clinical Oncology
Volume5
Issue number11
StatePublished - 1987

Fingerprint

Small Cell Lung Carcinoma
Vincristine
Doxorubicin
Cyclophosphamide
Granulocytes
Neoplasms
Induction Chemotherapy
Survival
Poisons
Leukopenia
Disease Progression
Therapeutics
Blood Platelets
Recurrence
Drug Therapy
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer : A phase III trial of the Southeastern Cancer Study Group. / Johnson, D. H.; Einhorn, L. H.; Birch, R.; Vollmer, R.; Perez, C.; Krauss, S.; Omura, G.; Greco, F. A.

In: Journal of Clinical Oncology, Vol. 5, No. 11, 1987, p. 1731-1738.

Research output: Contribution to journalArticle

@article{fd85d81ec53f435caa12515239a84a1e,
title = "A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group",
abstract = "To assess the effect of dose escalation in the treatment of small-cell lung cancer (SCLC), 298 patients with extensive-stage disease were treated with either conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2), (CDCAV); or high-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV). No dose attenuation was allowed during the initial three cycles of therapy in either treatment arm. All patients received CDCAV in cycles 4 through 6, during which time dosages were adjusted according to granulocyte and platelet nadirs. No additional chemotherapy was administered until disease progression or relapse was documented. Complete responses were more frequent with HDCAV (22{\%} v 12{\%}; P=.045). However, overall response rate (63{\%} v 53{\%}) and median survival (29.3 v 34.7 weeks) were not significantly different (P>.05). HDCAV was substantially more toxic than CDCAV, causing more episodes of life-threatening leukopenia (ie, granulocytes < 500/μL; 79{\%} v 40{\%}; P<.05) and infections (15{\%} v 4{\%}; P<.05). Dose intensification of cyclophosphamide and doxorubicin during induction chemotherapy did not produce any survival benefit compared with conventional dosages of these agents in SCLC patients with extensive-stage disease.",
author = "Johnson, {D. H.} and Einhorn, {L. H.} and R. Birch and R. Vollmer and C. Perez and S. Krauss and G. Omura and Greco, {F. A.}",
year = "1987",
language = "English (US)",
volume = "5",
pages = "1731--1738",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer

T2 - A phase III trial of the Southeastern Cancer Study Group

AU - Johnson, D. H.

AU - Einhorn, L. H.

AU - Birch, R.

AU - Vollmer, R.

AU - Perez, C.

AU - Krauss, S.

AU - Omura, G.

AU - Greco, F. A.

PY - 1987

Y1 - 1987

N2 - To assess the effect of dose escalation in the treatment of small-cell lung cancer (SCLC), 298 patients with extensive-stage disease were treated with either conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2), (CDCAV); or high-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV). No dose attenuation was allowed during the initial three cycles of therapy in either treatment arm. All patients received CDCAV in cycles 4 through 6, during which time dosages were adjusted according to granulocyte and platelet nadirs. No additional chemotherapy was administered until disease progression or relapse was documented. Complete responses were more frequent with HDCAV (22% v 12%; P=.045). However, overall response rate (63% v 53%) and median survival (29.3 v 34.7 weeks) were not significantly different (P>.05). HDCAV was substantially more toxic than CDCAV, causing more episodes of life-threatening leukopenia (ie, granulocytes < 500/μL; 79% v 40%; P<.05) and infections (15% v 4%; P<.05). Dose intensification of cyclophosphamide and doxorubicin during induction chemotherapy did not produce any survival benefit compared with conventional dosages of these agents in SCLC patients with extensive-stage disease.

AB - To assess the effect of dose escalation in the treatment of small-cell lung cancer (SCLC), 298 patients with extensive-stage disease were treated with either conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2), (CDCAV); or high-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV). No dose attenuation was allowed during the initial three cycles of therapy in either treatment arm. All patients received CDCAV in cycles 4 through 6, during which time dosages were adjusted according to granulocyte and platelet nadirs. No additional chemotherapy was administered until disease progression or relapse was documented. Complete responses were more frequent with HDCAV (22% v 12%; P=.045). However, overall response rate (63% v 53%) and median survival (29.3 v 34.7 weeks) were not significantly different (P>.05). HDCAV was substantially more toxic than CDCAV, causing more episodes of life-threatening leukopenia (ie, granulocytes < 500/μL; 79% v 40%; P<.05) and infections (15% v 4%; P<.05). Dose intensification of cyclophosphamide and doxorubicin during induction chemotherapy did not produce any survival benefit compared with conventional dosages of these agents in SCLC patients with extensive-stage disease.

UR - http://www.scopus.com/inward/record.url?scp=0023610106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023610106&partnerID=8YFLogxK

M3 - Article

C2 - 2824707

AN - SCOPUS:0023610106

VL - 5

SP - 1731

EP - 1738

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -